BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo. COVID-19 vaccine maker BioNTech, which is renewing its focus on its traditional roots in oncology, said in a joint statement with China's Duality that their drug would be tested on women with a certain type of advanced breast cancer with low levels of a cell surface receptor known as HER2. Partners Astra and Daiichi have taken the concept further with their leading drug Enhertu, based on the antibody-drug conjugate technology, a type of high-precision chemotherapy.
1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months vs 5.8 months with an HR 0.44). 2. Grade 3-4 adverse events occurred in 57% of the subtyping-based group and 31% in the control group with the most common being neutropenia, anemia, and increased alanine
The Max Foundation (Max), a leading global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients globally today announced Eli Lilly and Company will provide free of charge access to Verzenio® (abemaciclib) for the treatment of HR-positive, HER2-negative ABC for patients in Kenya.